Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down After Earnings Miss

Rapport Therapeutics, Inc. (NASDAQ:RAPP) gapped down prior to trading on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $30.54, but opened at $29.20. Rapport Therapeutics shares last traded at $30.50, with a volume of 115,263 shares.

The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.07).

More Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Phase‑2a efficacy and Phase‑3 timing — RAP‑219 showed robust, consistent activity in patients with focal‑onset seizures in a Phase 2a trial and Rapport expects to initiate a Phase‑3 program in Q2 2026; the program was also expanded into primary generalized tonic‑clonic seizures and bipolar mania based on the data. GlobeNewswire: Financial Results & Business Update
• Positive Sentiment: China deal provides non‑dilutive cash and upside — Rapport granted Tenacia exclusive Greater China rights to RAP‑219 and will receive $20M upfront, up to $308M in development/commercial milestones and tiered royalties, accelerating regional development and de‑risking part of the program. FierceBiotech: Tenacia deal
• Positive Sentiment: Strong cash runway — Rapport ended 2025 with $490.5M in cash, equivalents and short‑term investments, which management says should fund operations into H2 2029, reducing near‑term financing risk. GlobeNewswire: Financial Results & Business Update
• Neutral Sentiment: Insider sale — COO Cheryl Gault sold 2,014 shares (~$58k) on March 5; the sale is small relative to her remaining holdings and may reflect diversification rather than negative company news. SEC filing / MarketBeat: Insider sale
• Negative Sentiment: Quarterly EPS miss — Rapport reported Q4 EPS of ($0.72), missing consensus of ($0.65) by $0.07, which likely pressured the stock despite reassuring commentary on cash and pipeline progress. Quarterly press release (Quartr)

Wall Street Analysts Forecast Growth

RAPP has been the subject of several research analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Rapport Therapeutics in a research report on Friday, December 19th. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a report on Monday. Wells Fargo & Company started coverage on Rapport Therapeutics in a report on Monday, February 2nd. They set an “overweight” rating and a $43.00 price objective for the company. Wall Street Zen raised Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Citigroup reiterated a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Rapport Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $50.80.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, insider Krishnaswamy Yeleswaram sold 2,840 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total transaction of $85,342.00. Following the completion of the sale, the insider directly owned 296,991 shares in the company, valued at $8,924,579.55. The trade was a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David Bredt sold 8,500 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $29.02, for a total transaction of $246,670.00. Following the completion of the sale, the insider directly owned 387,075 shares of the company’s stock, valued at $11,232,916.50. The trade was a 2.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 69,669 shares of company stock worth $1,999,877 in the last quarter. Company insiders own 13.57% of the company’s stock.

Hedge Funds Weigh In On Rapport Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Meeder Asset Management Inc. acquired a new stake in Rapport Therapeutics in the 4th quarter valued at $37,000. Russell Investments Group Ltd. acquired a new position in shares of Rapport Therapeutics during the third quarter worth about $43,000. Strs Ohio lifted its stake in shares of Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after purchasing an additional 400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after buying an additional 905 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Rapport Therapeutics by 86.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after buying an additional 4,582 shares during the period.

Rapport Therapeutics Stock Down 3.0%

The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -10.93 and a beta of 1.51. The business has a 50 day moving average price of $28.14 and a 200-day moving average price of $26.86.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.